NEW YORK and LONDON, January 13, 2015 Topline data from double-blind portion of trial expected by end of February, 2015 Celsus Therapeutics (NASDAQ: …
Celsus Therapeutics Announces FDA Allowance of IND for Clinical Development of MRX-6 Cream in Atopic Dermatitis
NEW YORK and LONDON, January 12, 2015 Phase II dose ranging clinical trial in atopic dermatitis expected to begin in first quarter of 2015 Celsus …
Celsus Therapeutics Announces Upcoming Presentation at Oppenheimer 25th Annual Healthcare Conference
NEW YORK and LONDON, December 2, 2014 Celsus Therapeutics (NASDAQ: CLTX), an emerging growth, development-stage biopharmaceutical company, announces that Gur …
Celsus Therapeutics Plc Announces First Patient Enrolled in Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis
NEW YORK AND LONDON Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, announced the first patient has been …
Celsus Therapeutics Plc Receives Approval from the Ministry of Health of Israel For Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients
NEW YORK AND LONDON Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, has received approval from the Israeli …
